(RTTNews) - Roche (RHHBY) announced positive topline results from its Phase 2 ZUPREME-1 study of Petrelintide, an investigational amylin analog for people living with overweight and obesity.
Obesity is recognized as the greatest single risk factor for chronic disease globally, with projections suggesting more than half the world's population could be living with overweight or obesity by 2035.
The trial met its primary endpoint, with participants achieving up to 10.7% mean body weight reduction at week 42, compared to just 1.7% with placebo.
Importantly, the treatment was well tolerated, with no cases of vomiting and no discontinuations due to gastrointestinal side effects at the maximally effective dose.
Petrelintide is once-weekly subcutaneous injection to help restore sensitivity to the satiety hormone leptin, enabling patients to feel full faster and sustain weight loss.
Roche highlighted that female participant in the study lost considerably more weight than male participants, underscoring the drug's potential impact across diverse patient groups.
The favorable tolerability profile supports Petrelintide's use both as monotherapy and as a combination partner. Roche plans to present full data, including nine-week safety follow-up at an upcoming medical congress.
Topline Results from a second Phase 2 trial ZUPREME-2 in patients with obesity and type 2 diabetes are expected in the second half of 2026, with a combination study of Petrelintide and CT-388 set to begin later this year.
Roche, through its collaboration with Zealand Pharma, is advancing Petrelintide as part of a broader cardiometabolic portfolio aimed at addressing this growing health challenge.
RHHBY has traded between $34.75 and $60.85 over the past year. The stock closed yesterday's trading at $54.22, down 6.23%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
